Boardroom Alpha
Boardroom Alpha
ATYR · Additional Proxy Materials (DEFA14A) · Filed March 26, 2026

Atyr Pharma Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
March 26, 2026
Ticker
ATYR
Accession
0001339970-26-000022
Boardroom Alpha · Filing insights

ATYR Pharma urges stockholders to vote FOR its slate and Proposals 2–5 at the May 11, 2026 annual meeting.

About Atyr Pharma Inc
Market cap
$56M
1Y TSR
−89.9%
3Y TSR
−35.2%
Board grade
C-
Sector
Healthcare
CEO
S Shukla Ms Sanjay
Last annual meeting: May 11, 2026 · View full Atyr Pharma Inc profile →
DEFA14A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

 

Filed by the Registrant

Filed by a party other than the Registrant

 

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material under § 240.14a-12

ATYR PHARMA, INC.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

No fee required

Fee paid previously with preliminary materials

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

 

img234901345_0.jpg

NAME & ADDRESS HERE You must use the 11-digit Control Number located in the box to vote via Internet, or to request proxy materials. Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders To Be Held on May 11, 2026 at 9:00a.m. Pacific Time. This communication is not a form of voting and presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The Notice, Proxy Statement, Annual Report, and directions to attend the meeting are available at https://web.viewproxy.com/atyr/2026 If you want to receive a paper or email copy of these documents, you must request one by following the instructions on the reverse side of this Notice on or before April 28, 2026 to facilitate timely delivery. There is no charge to you for requesting a copy. Important information regarding the availability of the Company’s proxy materials, instructions for accessing your proxy materials and voting online, and instructions for requesting paper or e-mail copies of your proxy materials are outlined in this Notice. CONTROL NUMBER STOCKHOLDERS ARE CORDIALLY INVITED TO ATTEND THE ANNUAL MEETING. To the Stockholders of ATYR PHARMA, INC.: The 2026 Annual Meeting of Stockholders of ATYR PHARMA, INC. will be held on May 11, 2026 at 9:00 a.m. Pacific Time. Notice is hereby given that the Annual Meeting of Stockholders of ATYR PHARMA, INC. will be held on May 11, 2026 at 9:00 a.m. Pacific Time at the offices of aTyr Pharma, Inc., 10240 Sorrento Valley Road, San Diego, CA 92121 for the following purposes: The Board recommends a vote “FOR” each of the Board of Directors’ nominees listed in Proposal 1 and “FOR” Proposals 2, 3, 4, and 5. 1. To elect three Class II directors, as nominated by the Company’s Board of Directors (the “Board of Directors”), to hold office until the 2029 annual meeting of stockholders or until their successors are duly elected and qualified; 01. Eric Benevich 02. Timothy P. Coughlin 03. Jane A. Gross, Ph.D. 2. To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026; 3. To approve, on an advisory basis, the compensation of the Company’s named executive officers; 4. To approve an amendment to the aTyr Pharma, Inc. 2015 Stock Option and Incentive Plan, as amended; 5. To approve an amendment to the Company’s Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 170,000,000 to 340,000,000 shares; and 6. To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.

 

 

 

 

 

 


 

 

 

 

img234901345_1.jpg

 

The Securities and Exchange Commission rules permit us to make our proxy materials available to our stockholders via the Internet. Materials for this Annual Meeting and future meetings may be requested by one of the following methods: CONTROL NUMBER Internet Go to https://web.viewproxy.com/atyr/2026. Have the 11-digit Control Number available when you access the website and follow the instructions. Telephone Call 1-877-777-2857 Toll Free E-Mail By e-mail at: requests@viewproxy.com * If requesting material by e-mail, please send a blank e-mail with the company name and your 11-digit Control Number in the subject line. No other requests, instructions, or other inquiries should be included within this email request. VOTING METHODS Via Internet prior to the Annual Meeting: Go to https://web.viewproxy.com/atyr/2026. Have your 11-digit Control Number available and follow the prompts. • Your electronic vote prior to the Annual Meeting authorizes the named proxies to vote your shares in the same manner as if you marked, signed, dated, and returned a proxy card. Via Mail: Request a paper copy of the materials which includes Follow the instructions on the proxy a proxy card. card for voting by mail. Via Telephone: Call 1-866-402-3905 Use any touch-tone telephone to vote your proxy. Have your proxy card available when you call. Follow the voting instructions to vote your shares.


From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Atyr Pharma Inc (ATYR)

Reference

Frequently asked questions

When did Atyr Pharma Inc file this DEFA14A?
Atyr Pharma Inc (ATYR) filed this Additional Proxy Materials (DEFA14A) with the SEC on March 26, 2026. The accession number assigned by EDGAR is 0001339970-26-000022.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
ATYR Pharma urges stockholders to vote FOR its slate and Proposals 2–5 at the May 11, 2026 annual meeting. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Atyr Pharma Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Atyr Pharma Inc has filed under CIK 1339970, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer